[HTML][HTML] Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: challenges and opportunities
Q Xie, P Zhang, Y Wang, W Mei, C Zeng - Frontiers in Oncology, 2022 - frontiersin.org
Hepatocellular carcinoma is one of the leading causes of cancer mortality globally, and its
incidence is increasing. Immune checkpoint therapy has revolutionized the treatment of …
incidence is increasing. Immune checkpoint therapy has revolutionized the treatment of …
[HTML][HTML] Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities
Q Xie, P Zhang, Y Wang, W Mei, C Zeng - Frontiers in Oncology, 2022 - ncbi.nlm.nih.gov
Hepatocellular carcinoma is one of the leading causes of cancer mortality globally, and its
incidence is increasing. Immune checkpoint therapy has revolutionized the treatment of …
incidence is increasing. Immune checkpoint therapy has revolutionized the treatment of …
Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities
Q Xie, P Zhang, Y Wang, W Mei… - Frontiers in …, 2022 - pubmed.ncbi.nlm.nih.gov
Hepatocellular carcinoma is one of the leading causes of cancer mortality globally, and its
incidence is increasing. Immune checkpoint therapy has revolutionized the treatment of …
incidence is increasing. Immune checkpoint therapy has revolutionized the treatment of …
Overcoming resistance to immune checkpoint inhibitors in hepatocellular carcinoma: Challenges and opportunities.
Q Xie, P Zhang, Y Wang, W Mei, C Zeng - Frontiers in Oncology, 2022 - europepmc.org
Hepatocellular carcinoma is one of the leading causes of cancer mortality globally, and its
incidence is increasing. Immune checkpoint therapy has revolutionized the treatment of …
incidence is increasing. Immune checkpoint therapy has revolutionized the treatment of …